Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon γ-Primed MSCs for Acute GVHD Prophylaxis After HCT
NCT04328714Phase 1Terminated
- Start
- Dec 2021
- Primary completion
- Jul 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of interferon gamma-primed mesenchymal stromal cells in graft-versus-host disease (GVHD) (2 arms). Primary endpoints: Number of successful preparations and deliveries of investigational product at Day 1, Number of adverse events attributed to the investigational product at Day 2 and 1 more. Started Dec 2021; status: terminated.
02
Drugs
interferon gamma-primed mesenchymal stromal cells
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04328714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04328714.